Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Les Laboratoires Servier

Thumbnail
March 17, 2021

Fresh antitrust push hits biopharma

Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.

Thumbnail
January 27, 2021

Agios strengthens the case for mitapivat

A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.

Article image
Vantage logo
January 26, 2021

Novartis goes up against Glaxo in Tim-3

Article image
Vantage logo
January 06, 2021

Astrazeneca shows megamergers were still possible in 2020

One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.

Article image
Vantage logo
December 21, 2020

Agios gets $1.8bn and a new focus

Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.

Article image
Vantage logo
November 20, 2020

Precision’s Arcus gets a second endorsement

Article image
Vantage logo
October 16, 2020

Small Galapagos setback prompts a bigger loss of sentiment

A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.

Article image
Vantage logo
September 11, 2020

Esmo 2020 preview – a kidney cancer showdown gets star billing

Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.

Article image
Vantage logo
May 14, 2020

Asco 2020 – early allogeneic Car-T promise

Article image
Vantage logo
May 14, 2020

Asco 2020 – abstract dump triggers first moves

An early look at data from the huge cancer conference boosts Allogene and Immunogen, while Arvinas and Cytomx suffer.

Article image
Vantage logo
March 24, 2020

Bispecifics keep the business development fires burning

Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.